Radionuclides for targeted therapy: physical properties
C Stokke, M Kvassheim, J Blakkisrud - Molecules, 2022 - mdpi.com
A search in PubMed revealed that 72 radionuclides have been considered for molecular or
functional targeted radionuclide therapy. As radionuclide therapies increase in number and …
functional targeted radionuclide therapy. As radionuclide therapies increase in number and …
Biological determinants of PSMA expression, regulation and heterogeneity in prostate cancer
Prostate-specific membrane antigen (PSMA) is an important cell-surface imaging biomarker
and therapeutic target in prostate cancer. The PSMA-targeted theranostic 177Lu-PSMA-617 …
and therapeutic target in prostate cancer. The PSMA-targeted theranostic 177Lu-PSMA-617 …
Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy
D Zboralski, A Hoehne, A Bredenbeck… - European journal of …, 2022 - Springer
Purpose Fibroblast activation protein (FAP) is a membrane-bound protease that has limited
expression in normal adult tissues but is highly expressed in the tumor microenvironment of …
expression in normal adult tissues but is highly expressed in the tumor microenvironment of …
PSMA-targeting radiopharmaceuticals for prostate cancer therapy: recent developments and future perspectives
M El Fakiri, NM Geis, N Ayada, M Eder, AC Eder - Cancers, 2021 - mdpi.com
Simple Summary One of the most frequently diagnosed cancer in men is adenocarcinoma of
the prostate. Once the disease is metastatic, only very limited treatment options are …
the prostate. Once the disease is metastatic, only very limited treatment options are …
Fibroblast activation protein targeted radiotherapy induces an immunogenic tumor microenvironment and enhances the efficacy of PD-1 immune checkpoint inhibition
D Zboralski, F Osterkamp, E Christensen… - European Journal of …, 2023 - Springer
Purpose FAP is a membrane-bound protease under investigation as a pan-cancer target,
given its high levels in tumors but limited expression in normal tissues. FAP-2286 is a …
given its high levels in tumors but limited expression in normal tissues. FAP-2286 is a …
Preclinical evaluation of [58mCo]Co-DOTA-PSMA-617 for Auger electron therapy of prostate cancer
C Baun, JH Dam, MG Hildebrandt, JD Ewald… - Scientific Reports, 2023 - nature.com
Prostate-specific membrane antigen (PSMA), highly expressed in prostate cancer, is a
promising target for radionuclide therapy. Auger electron-emitting radionuclides are well …
promising target for radionuclide therapy. Auger electron-emitting radionuclides are well …
An Overview of In Vitro Assays of 64Cu-, 68Ga-, 125I-, and 99mTc-Labelled Radiopharmaceuticals Using Radiometric Counters in the Era of Radiotheranostics
Radionuclides are unstable isotopes that mainly emit alpha (α), beta (β) or gamma (γ)
radiation through radiation decay. Therefore, they are used in the biomedical field to label …
radiation through radiation decay. Therefore, they are used in the biomedical field to label …
Radiochemical processing of nuclear-reactor-produced radiolanthanides for medical applications
M Van de Voorde, K Van Hecke, T Cardinaels… - Coordination Chemistry …, 2019 - Elsevier
Several radiolanthanides find their application in nuclear medicine because of their
favorable decay properties, the most important ones being 143 Pr, 149 Pm, 153 Sm, 165 Dy …
favorable decay properties, the most important ones being 143 Pr, 149 Pm, 153 Sm, 165 Dy …
In Vitro comparison of 213Bi- and 177Lu-radiation for peptide receptor radionuclide therapy
HS Chan, E De Blois, A Morgenstern, F Bruchertseifer… - PLoS …, 2017 - journals.plos.org
Background Absorbed doses for α-emitters are different from those for β-emitters, as the high
linear energy transfer (LET) nature of α-particles results in a very dense energy deposition …
linear energy transfer (LET) nature of α-particles results in a very dense energy deposition …
Estimation of absorbed dose to the kidneys in patients after treatment with 177Lu-octreotate: comparison between methods based on planar scintigraphy
M Larsson, P Bernhardt, JB Svensson, B Wängberg… - EJNMMI research, 2012 - Springer
Abstract Background Lu-[DOTA 0, Tyr 3]-octreotate (177 Lu-octreotate) is used to treat
neuroendocrine tumors with high somatostatin-receptor expression. 177 Lu-octreotate is …
neuroendocrine tumors with high somatostatin-receptor expression. 177 Lu-octreotate is …